| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 2001 |
| 1 | CYCLOPHOSPHAMIDE | 1717 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 1717 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1717 |
| 4 | PREDNISONE | 1517 |
| 5 | METHOTREXATE SODIUM | 1377 |
| 6 | DOXORUBICIN | 1248 |
| 7 | METHOTREXATE | 1079 |
| 8 | LENALIDOMIDE | 960 |
| 9 | PREDNISOLONE | 939 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPCORITAMAB-BYSP | 251 | 0.1876 |
| 1 | TAFASITAMAB-CXIX | 42 | 0.0464 |
| 2 | POLATUZUMAB VEDOTIN | 428 | 0.0420 |
| 3 | AXICABTAGENE CILOLEUCEL | 403 | 0.0397 |
| 4 | BENDAMUSTINE HCL | 421 | 0.0269 |
| 5 | ETOPOSIDE PHOSPHATE | 41 | 0.0251 |
| 6 | MOSUNETUZUMAB | 23 | 0.0208 |
| 7 | BENDAMUSTINE HYDROCHLORIDE | 174 | 0.0204 |
| 8 | GLOFITAMAB | 48 | 0.0177 |
| 9 | IFOSFAMIDE FOR INJECTION | 325 | 0.0151 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 2791 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 2098 |
| 2 | Alkylating Drug [EPC] | 1899 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 1082 |
| 4 | Thalidomide Analog [EPC] | 970 |
| 5 | Platinum-based Drug [EPC] | 789 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 577 |
| 7 | Topoisomerase Inhibitor [EPC] | 561 |
| 8 | Tumor Necrosis Factor Blocker [EPC] | 507 |
| 9 | Kinase Inhibitor [EPC] | 461 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 299 | 0.0739 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 403 | 0.0397 |
| 2 | Interleukin-6 Antagonist [EPC] | 14 | 0.0216 |
| 3 | Alkylating Drug [EPC] | 1899 | 0.0078 |
| 4 | Topoisomerase Inhibitor [EPC] | 561 | 0.0073 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 2098 | 0.0066 |
| 6 | Classical Complement Pathway Inhibitor [EPC] | 2 | 0.0062 |
| 7 | Selective T Cell Costimulation Blocker [EPC] | 28 | 0.0059 |
| 8 | Nuclear Export Inhibitor [EPC] | 46 | 0.0052 |
| 9 | Mucocutaneous Epithelial Cell Growth Factor [EPC] | 2 | 0.0051 |